Brucella abortus LPS Antibodies

Santa Cruz Biotechnology features a diverse variety of Brucella abortus LPS monoclonal antibodies, supporting research in understanding the pathogenic mechanisms of Brucella abortus. Brucella abortus LPS Antibodies are validated for various techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Brucella abortus is a significant zoonotic pathogen responsible for brucellosis, a disease that affects both animals and humans. The lipopolysaccharide (LPS) component of Brucella abortus plays a crucial role in its virulence, influencing immune response and bacterial survival within host cells. Understanding the interactions between Brucella abortus LPS and the immune system is vital for developing effective vaccines and therapeutic strategies. Researchers can utilize Brucella abortus LPS monoclonal antibodies to investigate host-pathogen interactions and cellular signaling pathways. Advanced detection methods enable precise localization and quantification of LPS molecules in various experimental settings. Comprehensive characterization of Brucella abortus LPS helps identify potential therapeutic targets and vaccine candidates. Santa Cruz Biotechnology monoclonal antibodies for Brucella abortus LPS research support scientists worldwide in their mission to combat brucellosis and improve public health outcomes.